• Blood cell DNA methylation biomarkers in preclinical malignant pleural mesothelioma: The EPIC prospective cohort 

      Allione, Alessandra; Viberti, Clara; Cotellessa, Ilaria; Catalano, Chiara; Casalone, Elisabetta; Cugliari, Giovanni; Russo, Alessia; Guarrera, Simonetta; Mirabelli, Dario; Sacerdote, Carlotta; Gentile, Marco; Eichelmann, Fabian; Schulze, Matthias B.; Harlid, Sophia; Eriksen, Anne Kirstine; Tjønneland, Anne; Andersson, Martin; Dollé, Martijn E.T.; Van Puyvelde, Heleen; Weiderpass, Elisabete; Rodriguez-Barranco, Miguel; Agudo, Antonio; Heath, Alicia K.; Chirlaque, María-Dolores; Truong, Thérèse; Dragic, Dzevka; Severi, Gianluca; Sieri, Sabina; Sandanger, Torkjel M; Ardanaz, Eva; Vineis, Paolo; Matullo, Giuseppe (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-10-28)
      Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer mainly caused by asbestos exposure. Specific and sensitive noninvasive biomarkers may facilitate and enhance screening programs for the early detection of cancer. We investigated DNA methylation (DNAm) profiles in MPM prediagnostic blood samples in a case-control study nested in the European Prospective Investigation into Cancer ...